Vivaldi Capital Management’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Vivaldi Capital Management’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,590	Closed	-$433K	–	78
2026 Q1	$433K	Buy	12,590 +1,741	+16%	+$59.5K	0.06%	175
2025 Q4	$357K	Buy	10,849 +1,059	+11%	+$33K	0.05%	195
2025 Q3	$279K	Buy	9,790 +384	+4%	+$10.4K	0.04%	227
2025 Q2	$241K	Sell	9,406 -1,714	-15%	-$43.4K	0.04%	256
2025 Q1	$306K	Buy	11,120 +2,443	+28%	+$67.7K	0.05%	204
2024 Q4	$243K	Buy	8,677 +1,171	+16%	+$32.9K	0.04%	238
2024 Q3	$216K	Sell	7,506 -541	-7%	-$15.5K	0.06%	205
2024 Q2	$219K	Sell	8,047 -492	-6%	-$13.2K	0.06%	208
2024 Q1	$229K	Buy	+8,539	New	+$235K	0.07%	201

Other funds holding FTXH

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

MIM

Marshall Investment Management Littleton, Colorado $241M AUM 30.53% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vivaldi Capital Management's FTXH Position: Q2 2026 in Review

Vivaldi Capital Management sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q2 2026, closing a stake of 12,590 shares — an estimated $433K sold.

Vivaldi Capital Management first reported a position in FTXH in Q1 2024 and held it in 9 quarters. The position peaked at $433K in Q1 2026. 31 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

Vivaldi Capital Management reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q2 2026 after selling out during the quarter.
Vivaldi Capital Management sold 12,590 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2026, an estimated $433K.
Vivaldi Capital Management first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q1 2024 and held it in 9 quarters.
Vivaldi Capital Management's First Trust Nasdaq Pharmaceuticals ETF position peaked at $433K in Q1 2026.
31 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on Vivaldi Capital Management's 13F filing for Q2 2026.